These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31401638)

  • 1. Pharmacogenetic Markers: A Path toward Individualized HIV Therapy.
    García-Blanco D; Gravier-Hernández R; Rabeiro-Martínez CL; Gil Del Valle L; Pérez-Ávila J
    MEDICC Rev; 2019; 21(2-3):59-68. PubMed ID: 31401638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.
    Calcagno A; Cusato J; D'Avolio A; Bonora S
    Clin Pharmacokinet; 2017 Apr; 56(4):355-369. PubMed ID: 27641153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision medicine for HIV: where are we?
    Cusato J; Allegra S; Nicolò A; Calcagno A; D'Avolio A
    Pharmacogenomics; 2018 Jan; 19(2):145-165. PubMed ID: 29202676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
    Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA
    Pharmacol Rev; 2012 Jul; 64(3):803-33. PubMed ID: 22759796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic considerations in the treatment of HIV.
    Mattevi VS; Tagliari CF
    Pharmacogenomics; 2017 Jan; 18(1):85-98. PubMed ID: 27976978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
    Cressey TR; Lallemant M
    Infect Genet Evol; 2007 Mar; 7(2):333-42. PubMed ID: 17045554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV pharmacogenomics: closer to personalized therapy?
    Payne DA; Bryant BJ;
    Am J Pharmacogenomics; 2004; 4(3):141-50. PubMed ID: 15174895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics in HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nacher I; Rendón A; Soriano V
    AIDS Rev; 2005; 7(2):103-12. PubMed ID: 16092504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.
    Neary M; Owen A
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1169-1181. PubMed ID: 28994310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.
    Rutherford GW; Sangani PR; Kennedy GE
    Cochrane Database Syst Rev; 2003; (4):CD002037. PubMed ID: 14583945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host determinants of antiretroviral drug activity.
    Boffito M; Winston A; Owen A
    Curr Opin Infect Dis; 2005 Dec; 18(6):543-9. PubMed ID: 16258330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
    Vidal F; Domingo P; Viladés C; Peraire J; Arnedo M; Alcamí J; Leal M; Villarroya F; Gatell JM
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1365-82. PubMed ID: 21999362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will pharmacogenomic discoveries improve HIV therapeutics?
    Haas DW
    Top HIV Med; 2005; 13(3):90-5. PubMed ID: 16170225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.
    Martin AM; Nolan D; Gaudieri S; Phillips E; Mallal S
    Pharmacogenomics; 2004 Sep; 5(6):643-55. PubMed ID: 15335286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.
    Desta Z; Gammal RS; Gong L; Whirl-Carrillo M; Gaur AH; Sukasem C; Hockings J; Myers A; Swart M; Tyndale RF; Masimirembwa C; Iwuchukwu OF; Chirwa S; Lennox J; Gaedigk A; Klein TE; Haas DW
    Clin Pharmacol Ther; 2019 Oct; 106(4):726-733. PubMed ID: 31006110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dawn of precision medicine in HIV: state of the art of pharmacotherapy.
    Mu Y; Kodidela S; Wang Y; Kumar S; Cory TJ
    Expert Opin Pharmacother; 2018 Oct; 19(14):1581-1595. PubMed ID: 30234392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.
    Yu ZJ; Mosher EP; Bumpus NN
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():565-585. PubMed ID: 32960701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.
    Rutherford GW; Feldman KA; Kennedy GE
    Cochrane Database Syst Rev; 2000; (2):CD002037. PubMed ID: 10796850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.